About Zona pellucida-like domain-containing protein 1
Zona pellucida-like domain-containing protein 1 (ZPLD1) is a protein
from Homo sapiens identified by UniProt accession
Q8TCW7, 415 residues long.
MolForge cross-references it against 0 known binders and
57 disease associations.
Target properties
| Protein name | Zona pellucida-like domain-containing protein 1 |
| UniProt accession | Q8TCW7 |
| Gene | ZPLD1 |
| Organism | Homo sapiens |
| Length | 415 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (57)
Diseases linked to this target (Open Targets).
- C-reactive protein measurement · score 0.37
- multiple sclerosis · score 0.35
- aspartate aminotransferase measurement · score 0.34
- anxiety disorder · score 0.32
- neurodegenerative disease · score 0.30
- adolescent idiopathic scoliosis · score 0.30
- asthma · score 0.26
- triglyceride measurement · score 0.25
- cirrhosis of liver · score 0.25
- dry age related macular degeneration · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8TCW7-F1 | alphafold | PREDICTED | 77.27 | — |
Amino-acid sequence (415 residues)
MEQIWLLLLL TIRVLPGSAQ FNGYNCDANL HSRFPAERDI SVYCGVQAIT MKINFCTVLF SGYSETDLAL NGRHGDSHCR GFINNNTFPA VVIFIINLST LEGCGNNLVV STIPGVSAYG NATSVQVGNI SGYIDTPDPP TIISYLPGLL YKFSCSYPLE YLVNNTQLAS SSAAISVREN NGTFVSTLNL LLYNDSTYNQ QLIIPSIGLP LKTKVFAAVQ ATNLDGRWNV LMDYCYTTPS GNPNDDIRYD LFLSCDKDPQ TTVIENGRSQ RGRFSFEVFR FVKHKNQKMS TVFLHCVTKL CRADDCPFLM PICSHRERRD AGRRTTWSPQ SSSGSAVLSA GPIITRSDET PTNNSQLGSP SMPPFQLNAI TSALISGMVI LGVTSFSLLL CSLALLHRKG PTSLVLNGIR NPVFD
Explore Zona pellucida-like domain-containing protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets